Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) shares were up 6% during mid-day trading on Thursday after Robert W. Baird raised their price target on the stock from $8.00 to $10.00. Robert W. Baird currently has an outperform rating on the stock. Maravai LifeSciences traded as high as $9.53 and last traded at $9.40. Approximately 457,966 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 2,458,451 shares. The stock had previously closed at $8.87.
Several other analysts have also issued reports on the stock. Craig Hallum started coverage on shares of Maravai LifeSciences in a report on Wednesday, April 10th. They issued a "buy" rating and a $15.00 price objective on the stock. Stifel Nicolaus decreased their price objective on shares of Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 23rd. Finally, Royal Bank of Canada boosted their target price on Maravai LifeSciences from $12.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $11.44.
Check Out Our Latest Stock Report on MRVI
Institutional Trading of Maravai LifeSciences
A number of large investors have recently modified their holdings of MRVI. Gladius Capital Management LP acquired a new position in shares of Maravai LifeSciences during the fourth quarter worth about $30,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Maravai LifeSciences by 96.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company's stock worth $34,000 after purchasing an additional 1,662 shares during the last quarter. Signaturefd LLC grew its stake in shares of Maravai LifeSciences by 99.9% during the third quarter. Signaturefd LLC now owns 3,364 shares of the company's stock worth $34,000 after purchasing an additional 1,681 shares in the last quarter. Performa Ltd US LLC raised its stake in Maravai LifeSciences by 112.4% in the fourth quarter. Performa Ltd US LLC now owns 6,000 shares of the company's stock valued at $39,000 after buying an additional 3,175 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Maravai LifeSciences during the 1st quarter worth about $42,000. Hedge funds and other institutional investors own 50.25% of the company's stock.
Maravai LifeSciences Trading Up 11.2 %
The company has a debt-to-equity ratio of 0.70, a quick ratio of 7.41 and a current ratio of 8.00. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -10.47 and a beta of 0.03. The company has a 50-day moving average price of $8.09 and a 200-day moving average price of $6.73.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). The company had revenue of $74.14 million for the quarter, compared to analyst estimates of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. As a group, research analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current fiscal year.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Stories
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
